ESMO World Congress on Gastrointestinal Cancer | Conference

Second-Line Cetuximab Shows PFS Benefit in Wild-Type mCRC

July 4th 2015

Patients with metastatic colorectal cancer benefited from treatment with cetuximab plus chemotherapy even after disease progression on a similar regimen as long as their tumors did not harbor mutations in any of four key genes.

Dr. Howard S. Hochster on TAS-102 Compared to 5FU

July 4th 2015

Howard S. Hochster, MD, professor of Medicine and Associate Director for Clinical Sciences, Yale Cancer Center, discusses the potential of TAS-102 for colorectal cancer.

Survival Benefit of Regorafenib Confirmed in Combined Analysis of CORRECT and CONCUR

July 4th 2015

The survival benefit observed with regorafenib (Stivarga) over placebo in Asian patients who had been previously treated for metastatic colorectal cancer in the international phase III CORRECT trial was confirmed by the phase III CONCUR trial.

Dr. Lorenza Rimassa on Tivantinib for EGFR Inhibitor-Resistant mCRC

July 4th 2015

Lorenza Rimassa, MD, Deputy Director - Medical Oncology Unit - Humanitas Cancer Center, Humanitas Research Hospital, discusses a study looking at tivantinib (ARQ 197), a highly selective MET inhibitor, for the treatment of Metastatic Colorectal Cancer (mCRC).

Regorafenib Benefits Consistent in "Real World" mCRC Population

July 3rd 2015

Findings from a large expanded access program have confirmed the efficacy and safety of regorafenib in patients with previously treated metastatic colorectal cancer.

Improved OS, PFS Demonstrated by TAS-102, Regardless of KRAS Status

July 3rd 2015

TAS-102 demonstrated similar improvements in overall survival and progression-free survival in patients with heavily pretreated colorectal cancer from the phase III RECOURSE trial stratified by KRAS mutational status.

Adding Aprepitant Improves Control of Oxaliplatin-Related Nausea, Vomiting in CRC

July 3rd 2015

Adding an NK1 antagonist to a 5-HT3 receptor antagonist with dexamethasone improved antiemetic control for patients with colorectal cancer treated with an oxaliplatin-based regimen compared with the 5-HT3 antagonist and dexamethasone alone.

Dr. Andrew Zhu on Ramucirumab for HCC

July 3rd 2015

Andrew Zhu, MD, PhD, Associate Professor, Medicine, Harvard Medical School Director, Liver Cancer Research, Medicine, Massachusetts General Hospital, discusses the REACH study, which looks at ramucirumab in advanced hepatocellular carcinoma.

New Agents Show Promise in Gastric Cancer

July 3rd 2015

Josep Tabernero, MD, PhD, summarized novel agents that are currently under exploration for patients with gastric cancer.

Dr. Eric Van Cutsem on Regorafenib for Metastatic Colorectal Cancer

July 3rd 2015

Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses the safety profile of the phase III B CONSIGN study, which looked at regorafenib in patients with previously treated metastatic colorectal cancer (mCRC).

Hepatitis C "Revolution" May Transform Liver Cancer Outcomes

July 2nd 2015

Novel agents that target the replication of the hepatitis C virus are poised to have a far-reaching impact on the prevention and recurrence of hepatocellular carcinoma and have shown the ability to reverse liver fibrosis, including cirrhosis in patients with end-stage HCC.

IMM-101 Active, Maintains QoL in Patients with Metastatic Pancreatic Cancer

July 2nd 2015

Investigators reported a clinically meaningful extension of overall survival with IMM-101 plus gemcitabine in patients with metastatic pancreatic cancer.

Dr. Dirk Arnold on Sirflox Study Results in Colorectal Cancer

July 2nd 2015

Dirk Arnold, MD, director of the Department of Medical Oncology at Klinik fÃ¼r Tumorbiologie, Freiburg, Germany, discusses the phase III Sirflox study, which looked at selective internal radiation therapy (SIRT) using Yttrium-90 (Y-90) resin microspheres for the treatment of metastatic colorectal cancer.

Dr. Philip on Evofosfamide for Pancreatic Cancer

July 2nd 2015

Philip Philip MD, PhD, professor of oncology at Karmanos Cancer Center, Wayne State University School of Medicine, discusses the use of the investigational drug evofosfamide for pancreatic cancer.

Dr. Hendifar on PEGPH20 Survival Impact in High Hyaluronan Pancreatic Cancer

July 1st 2015

Andrew Hendifar, MD, MPH, Assistant Professor of Medicine at Cedars Sinai Medical Center and the David Geffen School of Medicine, discusses the use of a PEGylated form of rHuPH20 (PEGPH20) added to nab-paclitaxel/gemcitabine for pancreatic cancer patients with high levels of hyaluronan (HA).

Low BMI Prognostic for Worse Survival in Colorectal Cancer

July 1st 2015

Results from a pooled dataset of more than 6000 patients with metastatic colorectal cancer found an association between low body mass index and a worse median overall survival with first-line bevacizumab and chemotherapy, suggesting that low BMI could be a prognostic factor for worse outcomes.

Dr. Zafar on Low BMI Impact on Colorectal Cancer Survival

July 1st 2015

S. Yousuf Zafar, MD, Associate Professor of Medicine at Duke Cancer Institute, discusses the potential link between low body mass index (BMI) and survival outcomes in metastatic colorectal cancer.

Dr. Fakih on Advances in Liver-Directed Therapies in CRC

July 3rd 2014

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses recent advances in liver-directed therapies in colorectal cancer (CRC).

Dr. Arnold on a Phase III Trial Examining Options for Maintenance Therapy in mCRC

July 2nd 2014

Dirk Arnold, MD, director, Department of Medical Oncology, Tumour Biology Centre, Freiburg, Germany, discusses a phase III trial looking at options for maintenance therapy for metastatic colorectal cancer (mCRC).

Dr. Yoshino Discusses the Safety Profile of TAS-102

June 30th 2014

Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses the safety profile of TAS-102 as seen in a phase III study of the agent versus placebo, with best supportive care, in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.